Kymanox
Andrew Messick serves as the Chief Financial Officer at Kymanox since April 2025. Prior to this role, Messick held the position of Chief Financial Officer at Sabai Global from September 2020 to April 2025, overseeing finance for a prominent provider of clinical research and biosafety services, which includes various subsidiaries. Messick also served as Chief Financial Officer for PeriGen from September 2017 to October 2019, where responsibilities included financial strategy and post-acquisition integration. Earlier experience includes a tenure as Vice President of Finance at WCG and Chief Financial Officer at Copernicus Group IRB, both contributing to financial leadership and strategic planning within the clinical research sector. Messick holds a Master’s degree in Accountancy and a Bachelor of Science in Business Administration from UNC Kenan-Flagler Business School.
This person is not in any teams
This person is not in any offices
Kymanox
Kymanox (KI’-MAH-NOKS’) means Ideal Knowledge Transfer. Leveraging our experienced team and intellectual assets, we provide a broad range of technical services and products. Our core competencies include Project Management, Quality and Compliance, Technical Operations, and Validation. Headquartered in North Carolina, Kymanox has successfully delivered projects across the globe. Kymanox is Your Life Science Solutions Partner. We are a premier technical products and project management company. We are experts in providing our clients in the Biotechnology, Pharmaceutical, and Medical Device, and Combination Product industries with engineering, scientific, regulatory, and process operations support. We help bring products from bench to patient. We differentiate ourselves by offering a broad range of technical services and products with turnkey project delivery. We serve clients globally from our headquarters in Durham (RTP), North Carolina and branch hubs across the US.